Reuters, Ben Hirschler
In developed and developing countries alike, patients and governments are struggling to pay for modern drugs that are revolutionizing cancer care but may cost tens of thousands of dollars a year for each patient.
"It's very frustrating," says Workman, who heads up the drug discovery unit at the Institute of Cancer Research (ICR), which is funded in large part by charities.
What is needed, he believes, is a new model that takes advantage of the highly specific nature of modern targeted therapies to slash drug development timelines and costs.
In the long term, Workman is convinced that will happen. But for the moment the world is caught in a pinch point as global drug companies put sky-high price tags on cancer medicines in a bid to recoup development costs for drugs aimed at a relatively small number of cancer sufferers.
The strains are growing—whether in Europe, where austerity has savaged healthcare budgets, or in the United States, where out-of-pocket costs can bankrupt patients, or in the developing world, where price tags of around $5,000 for a month's drug supply are simply out of reach. . .View Full Article
"ARNI's chairman is one of the best in the world in the urology field, and the company's consortium of investors has given us a lot of validation." (4/3/14) Arno Therapeutics Inc. - The Life Sciences Report Interview with Ran Nussbaum More >
"Positive clinical data will make CTH's APL-130277 a very attractive asset for specialty pharma or large pharma." (3/19/14) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Stephen Ireland More >
Chasing Cheaper Cancer Drugs
Source: Reuters, Ben Hirschler (4/2/12)
"A new model that takes advantage of the highly specific nature of modern targeted therapies could slash drug development timelines and costs."
Reuters, Ben Hirschler
Three views on living and investing in the U.S. Commonwealth
"PSTI's ability to vary the cell phenotype for a specific therapy is unique in the regenerative medicine space." (3/6/14) Pluristem Therapeutics Inc. - The Life Sciences Report Interview with George Zavoico More >
"The fact that CGIX was able to get a practiced sales force to take its products to market is a very big deal." (3/5/14) Cancer Genetics Inc. - The Life Sciences Report Interview with Ben Haynor More >
"NEO is in the process of launching next-generation sequencing for the clinical trial market; the deal with Covance sets the stage for the company to go to the next level." (2/27/14) NeoGenomics Laboratories - The Life Sciences Report Interview with Debjit Chattopadhyay More >